Cargando…
Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
BACKGROUND: Immune checkpoint inhibitors are effective therapies for a wide range of malignancies. Their increased use has led to a wide range of immune-related adverse effects including skin, gastrointestinal, pulmonary, endocrine, cardiac, and neurologic complications. CASE PRESENTATION: We presen...
Autores principales: | Cham, Jason, Ng, Daniel, Nicholson, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165972/ https://www.ncbi.nlm.nih.gov/pubmed/34053457 http://dx.doi.org/10.1186/s13256-021-02858-7 |
Ejemplares similares
-
Pembrolizumab‐induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer
por: Todo, Maki, et al.
Publicado: (2019) -
Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
por: Ünlütürk, Zeynep, et al.
Publicado: (2023) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
An Interesting Case Report of Myasthenia Gravis Exacerbation Induced by Durvalumab
por: Abidoye, Oluseyi, et al.
Publicado: (2022) -
Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
por: Bai, Jing, et al.
Publicado: (2022)